Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237286 | 0.89 | SIGMAR1 (0.55) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| SCHEMBL10902405 | 0.88 | MEN1 (0.67) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| SCHEMBL5858631 | 0.87 | SIGMAR1 (0.51) | SIGMAR1KCNH2MEN1KMT2ACYP1A2 | |
| SCHEMBL7772142 | 0.86 | SLC6A3 (0.61) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| SCHEMBL4699834 | 0.85 | SIGMAR1 (0.50) | SIGMAR1KCNH2MEN1KMT2ACYP1A2 | |
| SCHEMBL9610820 | 0.85 | EBP (0.55) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| SCHEMBL2741683 | 0.85 | HRH3 (0.62) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7447525 | 0.85 | SLC6A3 (0.59) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| SCHEMBL7031548 | 0.85 | HRH3 (0.62) | SIGMAR1EBPKCNH2MEN1KMT2A | |
| SCHEMBL65179 | 0.85 | HDAC6 (0.69) | KCNH2MEN1KMT2AHDAC6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008354-A | Protein kinase inhibitors | ORIBASE PHARMA | 2015-10-28 | — | — | CN | disclosed |
| CN-103342701-A | 2-Aminothiazole compound polycrystalline type as kinase inhibitors and preparation method thereof | AB SCIENCE | 2013-10-09 | — | — | CN | disclosed |
| CN-101657446-B | Method for synthesizing 2-aminothiazole compounds as kinase inhibitors | AB SCIENCE | 2013-05-15 | — | — | CN | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| CN-101657446-A | Method for synthesizing 2-aminothiazole compounds as kinase inhibitors | SCIENCE FR AB | 2010-02-24 | — | — | CN | disclosed |
| CN-100347162-C | N-phenyl-2-pyrimidinamine derivatives | NOVARTIS AG (CH) | 2007-11-07 | — | — | CN | disclosed |
| CN-101016262-A | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| CN-1630648-A | N-phenyl-2-pyrimidinamine derivatives | NOVARTIS AG (CH) | 2005-06-22 | — | — | CN | disclosed |
| US-4616086-A | ANTICOAGULANTS | BOEHRINGER MANNHEIM GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0076996-A1 | Carboxylic-acid derivatives, process for their preparation and medicines containing them | Roche Diagnostics GmbH (DE) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ABL1, JAK2, ABL2 | SIGMAR1 2016/4885EBP 4217/4885KCNH2 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.